Follow
Idit sagiv barfi
Idit sagiv barfi
Verified email at stanford.edu
Title
Cited by
Cited by
Year
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
A Marabelle, H Kohrt, I Sagiv-Barfi, B Ajami, RC Axtell, G Zhou, ...
The Journal of clinical investigation 123 (6), 2447-2463, 2013
4462013
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
I Sagiv-Barfi, HEK Kohrt, DK Czerwinski, PP Ng, BY Chang, R Levy
Proceedings of the National Academy of Sciences 112 (9), E966-E972, 2015
4342015
Eradication of spontaneous malignancy by local immunotherapy
I Sagiv-Barfi, DK Czerwinski, S Levy, IS Alam, AT Mayer, SS Gambhir, ...
Science translational medicine 10 (426), eaan4488, 2018
3602018
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
HE Kohrt, A Thielens, A Marabelle, I Sagiv-Barfi, C Sola, F Chanuc, ...
Blood, The Journal of the American Society of Hematology 123 (5), 678-686, 2014
3082014
Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
HE Kohrt, I Sagiv-Barfi, S Rafiq, SEM Herman, JP Butchar, C Cheney, ...
Blood, The Journal of the American Society of Hematology 123 (12), 1957-1960, 2014
2332014
Targeting CD137 enhances the efficacy of cetuximab
HE Kohrt, AD Colevas, R Houot, K Weiskopf, MJ Goldstein, P Lund, ...
The Journal of clinical investigation 124 (6), 2668-2682, 2014
1992014
Autologous iPSC-based vaccines elicit anti-tumor responses in vivo
NG Kooreman, Y Kim, PE de Almeida, V Termglinchan, S Diecke, ...
Cell stem cell 22 (4), 501-513. e7, 2018
1552018
Imaging activated T cells predicts response to cancer vaccines
IS Alam, AT Mayer, I Sagiv-Barfi, K Wang, O Vermesh, DK Czerwinski, ...
The Journal of clinical investigation 128 (6), 2569-2580, 2018
1192018
Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
R Levy, B Chang, P Ng, I Sagiv-barfi
1042015
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma
I Sagiv-Barfi, HE Kohrt, L Burckhardt, DK Czerwinski, R Levy
Blood, The Journal of the American Society of Hematology 125 (13), 2079-2086, 2015
822015
An mRNA SARS-CoV-2 vaccine employing charge-altering releasable transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory
OAW Haabeth, JJK Lohmeyer, A Sallets, TR Blake, I Sagiv-Barfi, ...
ACS Central Science 7 (7), 1191-1204, 2021
372021
Radiotherapy and toll-like receptor agonists
A Marabelle, A Filatenkov, I Sagiv-Barfi, H Kohrt
Seminars in Radiation Oncology 25 (1), 34-39, 2015
282015
Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonize rituximab-dependent NK-cell mediated cytotoxicity
N Rajasekaran, M Sadaram, J Hebb, I Sagiv-Barfi, S Ambulkar, ...
Blood 124 (21), 3118, 2014
272014
Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors
I Sagiv-Barfi, E Weiss, A Levitzki
Bioorganic & medicinal chemistry 18 (17), 6404-6413, 2010
262010
Intratumoral immunotherapy relies on B and T cell collaboration
I Sagiv-Barfi, DK Czerwinski, T Shree, JJK Lohmeyer, R Levy
Science immunology 7 (71), eabn5859, 2022
202022
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin …
C Chester, S Chang, JF Kurland, I Sagiv-Barfi, D Czerwinski, A Rajapaksa, ...
Journal of Clinical Oncology 32 (15_suppl), 3017-3017, 2014
202014
Neoadjuvant intratumoral immunotherapy with TLR9 activation and anti-OX40 antibody eradicates metastatic cancer
WX Hong, I Sagiv-Barfi, DK Czerwinski, A Sallets, R Levy
Cancer research 82 (7), 1396-1408, 2022
182022
Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression
CL Miller, I Sagiv-Barfi, P Neuhöfer, DK Czerwinski, SE Artandi, ...
Cell chemical biology 29 (3), 451-462. e8, 2022
152022
A color discriminating broad range cell staining technology for early detection of cell transformation.
AEAL Idit Sagiv, Pavel Idelevich, Ilia Rivkin, Rimona Margalit
Journal of Carcinogenesis, 2009
142009
Obinutuzumab (GA101) is less prone to antagonism of immune effector function by ibrutinib than rituximab in vitro and in vivo
S Herter, I Sagiv-Barfi, C Chester, M Sadaram, J Hebb, DK Czerwinski, ...
Blood 124 (21), 1765, 2014
132014
The system can't perform the operation now. Try again later.
Articles 1–20